©2022 Stanford Medicine
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
Trial ID: NCT03565991
Avelumab in combination with talazoparib will be investigated in patients with locally advanced or metastatic solid tumors with a BRCA or ATM defect.
A PHASE 2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH BRCA OR ATM MUTANT TUMORS JAVELIN BRCA/ATM
- BRCA1, BRCA2 and/or ATM gene defect.
- Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid
tumors that are not amenable for treatment with curative intent
- Availability a tumor tissue sample from a diagnostic biopsy/surgery or a metastatic
- Progressive disease at study enrollment.
- Minimum age 18 years (in Japan, minimum age 20 years).
- ECOG performance status 0 or 1.
- Adequate bone marrow, renal and liver function.
- For childbearing female patients, negative serum or urine pregnancy test at screening
- Signed and dated informed consent document.
- Prior anti-cancer therapy or radiation therapy within 2 weeks prior to enrolment.
Palliative radiotherapy to metastatic lesion(s) permitted providing that it has been
completed at least 2 days prior to enrolment and no significant toxicity are expected.
- Major surgery within 4 weeks prior to study enrollment.
- Current use of immunosuppressive medication at the time of study enrollment.
- Known prior severe hypersensitivity to investigational products or any component in
- Known history of immune-mediated colitis, inflammatory bowel disease, pneumonitis,
- Active or prior autoimmune disease that might deteriorate when receiving an
- Prior organ transplantation including allogenic stem-cell transplantation.
- Administration of live attenuated vaccines within 4 weeks of study enrollment.
- Diagnosis of myelodysplastic syndrome.
- Known symptomatic brain metastases requiring steroids.
- Persisting toxicity related to prior therapy Grade >1.
- Known history of HIV or AIDS.
- Positive HBV or HCV test indicating acute or chronic infection.
- Active infection requiring systemic therapy.
- Clinically significant (active) cardiovascular disease: cerebral vascular
accident/stroke or myocardial infarction within 6 months prior to study enrollment;
unstable angina, congestive heart failure or a serious cardiac arrhythmia requiring
- Diagnosis of any other malignancy within 2 years prior to study enrollment, except for
adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of
the breast, bladder, or cervix, or low-grade prostate cancer or other early-stage
- Pregnant or breastfeeding female patients; female or male patients who are able to
have children who are unable or unwilling to use contraception as outlined in the
School of Medicine
300 Pasteur Drive
Stanford, CA 94305